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CASE REPORT
TREATMENT OF CHRONIC HEPATITIS C IN NON-RESPONSIVE PATIENTS WITH
PEGYLATED INTERFERON ASSOCIATED WITH RIBAVIRIN AND THALIDOMIDE:
REPORT OF SIX CASES OF TOTAL REMISSION
Marcos Montani CASEIRO(1)
SUMMARY
Hepatitis C virus (HCV) infection is an important public health issue worldwide. It is estimated that over 170 million people
are infected with the virus. The present study reports six cases in which patients did not respond to combination therapy with
pegylated interferon and ribavirin. However, after the addition of thalidomide to the therapy, the patients presented negative RNA
PCR. The use of thalidomide combined with pegylated interferon and ribavirin for the treatment of hepatitis C is described here
for the first time in the related literature.
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INTRODUCTION
The World Health Organization has estimated that there are 170
million people infected with Hepatitis C (HCV), which means that
this infection is currently one of the most important public health issues
worldwide40. In 2001, there were around 1.4 million deaths caused by
chronic liver diseases, among which 796,000 were caused by cirrhosis
and 616,000 were caused by primary liver cancer (hepatocarcinoma).
Twenty percent (280,000) of the total number of deaths were probably
due to HCV infection21.
HCV infection is the primary cause of death in patients with chronic
liver diseases worldwide2,17,21,40. Combination therapy with pegylated
interferon (IFNp) and ribavirin is currently the only available treatment
for HCV approved by the Food and Drug Administration (FDA). This
therapy is given for 24 weeks for genotypes 2 and 3, and for 48 weeks
for genotype 1. Patients with genotype 1 undergoing IFNp-alfa-2b and
ribavirin combination therapy achieve a sustained viral response (SVR)
rate of 42%. Patients with genotypes 2 and 3 achieve an SVR rate of
82%46. SVR rates in patients undergoing IFN-alfa-2a and ribavirin
combination therapy are 46% and 76%, respectively27,33,46.
The success rate of the treatment is not yet optimal and, considering
the potential complications related to the long-term chronicity of HCV
infection, it is imperative that we explore other treatment options.
Thalidomide has several properties as a sedative-hypnotic,
immunomodulatory, anti-inflammatory and antiangiogenic drug.
Initially, it was indicated for nausea and caused human teratogenicity
in pregnant women. Currently, it has been indicated for the treatment
of cutaneous manifestations of erythema nodosum leprosum and has
been investigationally used in combination with anticancer drugs to
treat several types of carcinoma11,30,31,36,49,53,63,70,83. There exists no
published evidence that it has ever been tested in patients with chronic
hepatitis C.
CASE REPORT
A male patient with chronic HCV infection, aged 44 years, with
positive HCV antibodies identified in November 1996, and with
unknown exposure to HCV, sought the medical center for clinical
assessment on October 12, 1999. His liver function test showed alanine
aminotransferase (ALT) 86 U/L, aspartate aminotransferase (AST)
178 U/L, and initial viremia was determined by HCV RNA of 340,463
U/mL (genotype 1a). Liver biopsy showed structural lesion (level 3)
and steatosis.
In May 2001, the patient began therapy for HCV infection with
weekly injections of IFN 3,000,000 U and ribavirin, for a total of 12
months. At the end of this treatment, HCV RNA was 1,309,317 U/mL,
with ALT 151 U/L and AST U/L 272, which defined a non-responsive
case. The patient was then referred to our service for reevaluation. As
of October 2002, 1.5 µg/kg of IFNp alfa-2b once a week and 500 mg
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of ribavirin b.i.d. were administered to the patient for a total of 12
weeks. In January 2003, the viral load test showed HCV RNA of
2,126,000 U/mL and the patient complained of multiple ulcers, pain
and had difficulty to eat. No response to local therapy or anesthetics
and other medications was observed. In addition to IFN and ribavirin,
a dose of 100 mg of thalidomide was prescribed b.i.d. for 30 days to
treat the patient’s mouth ulcers. At the follow-up appointment, one
month later, the patient presented remission of the symptoms, and
reported that the ulcers had disappeared in one week. His liver function
test showed a decrease in AST (32 U/L) and ALT (40 U/L). Thalidomide
administration was maintained for 30 days. In May 2003, the HCV
RNA viral load was undetectable and in August 2003, the qualitative
polymerase chain reaction (PCR) was negative, as well as in October,
at the end of the treatment.
After this case, five other patients who presented no decrease in
HCV viral load after 12 weeks of weekly treatment with 1.5 µg/kg of
IFNp alfa-2b and 500 mg of ribavirin b.i.d. were treated with the same
dose of thalidomide for 30 days. Four patients presented negative HCV
PCR and one patient, who weighed 130 kg, had a decrease in HCV
viral load of 1 log at the follow-up appointment 30 days after
thalidomide use. Five patients presented sustained virologic response
(SVR) at 48 weeks and 72 weeks.
DISCUSSION
Various therapeutic approaches have been reported for the treatment
of hepatitis C in patients with no response to previous treatment
combining IFN (conventional or pegylated) and ribavirin. Among these
are the combination of IFN alpha + ribavirin + amantadine5,22,74,75,84, IFN
alpha + phlebotomy24,26,56,68, IFN alpha + prednisolone32,73, IFN
alpha + cimetidine, IFN alpha + N-acetylcysteine42,54, IFN alpha and
vitamin E43,45,57,67. In addition to these, other adjuvant therapies include
Levorin, glycyrrhizine10,28,39,41,52,55, ursodeoxycholic acid12,14,23,59,60,
Maxamine7, pentoxifylline, Isoprinosine61,80,87, colchicine5,25,64,65,
histamine34, IL-101,18,44, IL-1229,35,76,85,86, IL-28,13,37,66,72, IFN gamma9,16,69,
granulocyte colony-stimulating factor (G-CSF)47,78,81, granulocyte-
microphage colony-stimulating factor (GM-CSF)48,58,77, and thymosin
alpha 13,4,38,51,62. None of these approaches has proved more effective
than IFNp and ribavirin combination therapy. The present study
described the action of thalidomide and IFNp + ribavirin combination
therapy. The use of thalidomide against various pathologies is well
known11,30,31,36,49,53,63,70,82,83. However, no studies have reported its use in
HCV treatment. Various hypotheses can be formulated with regard to
the efficacy of thalidomide, for instance, as an immunomodulatory,
anti-inflammatory agent which inhibits TNF-alpha50, or even the effects
of thalidomide on lymphocytes, increasing interferon gamma
secretion79. Nevertheless, various questions remain. It is still unknown
whether thalidomide has any effect on viral replication; whether it
acts on the modulation of cytokines which act on the inflammatory
process of liver diseases caused by HCV; and whether it is necessary
to combine thalidomide with pegylated interferon and ribavirin. Other
questions to consider are the appropriate dose of thalidomide; the
duration of treatment; and the time to initiate treatment. Only a
randomized clinical trial can provide us with the answers. We have
already begun a pilot trial which will soon allow us to present more
consistent data.
RESUMO
Tratamento de hepatite C crônica em pacientes não
respondedores, com a associação interferon peguilado,
ribavirina e talidomida. Relato de seis casos
A infecção pelo vírus da Hepatite C (HCV) representa um
importante problema de saúde pública no mundo, estima-se que mais
de 170 milhões de pessoas estejam infectadas. Relatamos o encontro
de 6 pacientes não respondedores à associação de Interferon Peguilado
e Ribavirina que negativaram seu PCR–RNA após a associação com
talidomida. Trata-se do primeiro relato desta associação no tratamento
da hepatite C encontrado na literatura.
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